Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 66-71

  Sermet Gaudelus, Isabelle ^a  

^a INSERM   (France)

Author keywords

CFTR mutations; CFTR potentiator; Cystic fibrosis; G551D; Ivacaftor; Personalised medicine

Indexed keywords

ASPARTIC ACID; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLYCINE; IVACAFTOR; LUMACAFTOR; PLACEBO;

ABDOMINAL PAIN; AMINO ACID SUBSTITUTION; AUTOSOMAL RECESSIVE DISORDER; CHANNEL GATING; CHLORIDE SWEAT LEVEL; CHLORIDE TRANSPORT; COUGHING; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE REVISED; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GENE MUTATION; HOMOZYGOTE; HUMAN; NAUSEA; NONSENSE MUTATION; NOSE OBSTRUCTION; OROPHARYNX PAIN; PAIN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SWEAT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AMINOPHENOLS; CHILD; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; QUINOLONES; RESPIRATORY SYSTEM AGENTS; SWEAT; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874711555     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008512     Document Type: Review

References (24)

1. Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med 2012; 10: 88.
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
3. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011; 139: 1480-1490.
4. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23: 146-158.
5. De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013; 41: 203-216.
6. Elborn JS. Personalised medicine for cystic fibrosis: treating the basic defect. Eur Respir Rev 2013; 22: 3-5.
7. Derichs N. Targeting a genetic defect: cystic fibrosis transmem- brane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013; 22: 58-65.
8. Pettit RS. Cystic fibrosis transmembrane conductance regulator- modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother 2012; 46: 1065-1075.
9. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843-18848.
10. Bompadre SG, Sohma Y, Li M, et al. G551D and G1349D, two CF- associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol 2007; 129: 285-298.
11. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11: 237-245.
12. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Human Mutat 2002; 19: 575-606.
13. Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Human Mutat 1997; 10: 135-154.
14. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
15. Bronsveld I, Vermeulen F, Sands D, et al. Influence of perfusate temperature on nasal potential difference. Eur Respir J 2012 [Epub ahead of print DOI: 10.1183/09031936.00097712].
16. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-734.
17. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
18. Davies JCLH, Yen K, Ahrens R. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation. J Cyst Fibros 2012; 11: Suppl. 1, S13.
19. McKone ELH, Yen K, Davies JC. Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D- CFTR Mutation. J Cyst Fibros 2012; 11: Suppl. 1, S13.
20. Quittner AL, Buu A, Messer MA, et al. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005; 128: 2347-2354.
21. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-L1130.
22. Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 2001; 108: 1705-1715.
23. Veeze HJ, Halley DJ, Bijman J, et al. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994; 93: 461-466.
24. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012; 142: 718-724.